El interés en corto de Helius Medical Tech da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Helius Medical Tech. Los datos de interés en corto se actualizan cada dos semanas.

Helius Medical Tech (NASDAQ:HSDT) Bolsa, Informe de interés en corto

Helius Medical Tech

Helius Medical Technologies Inc is a neurotech company focused on neurological wellness. The company's purpose is to develop, license, or acquire non-invasive technologies targeted at reducing symptoms of neurological disease or trauma. The company's product, known as the Portable Neuromodulation Stimulator (PoNS) is authorized for sale in Canada as a class II, a non-implantable medical device intended for use as a short-term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with supervised therapeutic exercise.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ANAB

ASST

CCLD

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

DWTX

HSDT

HUBC

LSTA

NEHC

NFLX

SEPN

STFS

USEG

Netflix sorprende con un aumento en suscriptores y mejores pronósticos. Descubre también los mayores ganadores y perdedores del premercado.

Acciones de Netflix se disparan alrededor del 15%; 20 acciones que se están moviendo en el premercado de EE.UU.

APLD

AZTR

CRKN

CVGW

GCTK

GLAC

LFWD

MASS

ORKA

QBTS

QUBT

RIME

SGBX

VMAR

VRME

Descubre las acciones ganadoras y perdedoras en el premercado, con Vision Marine liderando un aumento del 45%.

Las acciones de Vision Marine (VMAR) se disparan un 45%; 20 acciones que se están moviendo en premercado

AMPG

AVGR

BIPC

CHEK

CREV

FDSB

KORE

LAES

LIND

NCRA

NEUE

NVNI

RELI

SLGL

TIVC

TLRY

TOVX

Carbon Revolution lidera con un aumento del 62,4% en el premercado. ¿Qué otras acciones destacaron antes de la apertura?

Las acciones de Carbon Revolution (CREV) están subiendo un 62%; 20 acciones que se están moviendo en el premercado

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Technologies Inc

Helius Medical Technologies Inc Warrants (02/02/2026)

JP Morgan analyst Samik Chatterjee maintains Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) with a Overweight and lowers the price target from $150 to $108.

Price Target

Analyst Ratings

DELL

JP Morgan Maintains Overweight on Dell Technologies, Lowers Price Target to $108

Stifel analyst Tore Svanberg maintains Analog Devices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADI#NASDAQ">ADI</a>) with a Buy and lowers the price target from $275 to $225.

Stifel Maintains Buy on Analog Devices, Lowers Price Target to $225

Good Morning Traders! In today&#8217;s Market Clubhouse Morning Memo, we will discuss SPY, QQQ, AAPL, MSFT, NVDA, GOOGL, META, and TSLA.
Our proprietary formula, exclusive to Market Clubhouse, dictates these price levels. This dynamic equation takes into account price, volume, and options flow. These levels are updated every day and shared with all Clubhouse Members, prior to the opening of the market.
We recommend closely monitoring these stocks, and be prepared to leverage potential breakouts or reversals. As always, stay alert and ready to adjust your tactics based on the market&#8217;s pulse to optimize your trading gains. Now, let&#8217;s dive into the stock analysis:
SPDR S&amp;P 500 ETF Trust (SPY)
SPY is currently trading near our pivot at 528.66. Bulls will first target a move upward towards 530.09, aiming to establish stability above this price. If buyers maintain control, expect further upward momentum towards 532.56. Sustained strength above this area could trigger additional upside, pushing towards 534.17. The highest bullish objective for today on SPY stands at 534.53.
Should 528.66 fail to offer support, bears will likely target a move down towards 526.31. Continued selling here might open the door to test lower levels around 525.26. If selling pressure intensifies below this threshold, expect the bears to press toward the significant support of 523.76. In the event of aggressive downside momentum today, the extreme bearish target is set at 521.85.
Invesco QQQ Trust Series 1 (QQQ)
QQQ is currently trading near our critical price point at 447.73. For bullish momentum to prevail, traders must successfully hold prices above this mark, aiming initially for stability at 449.36. Persistent buying would then encourage bulls to target 450.98 next. Strong upside participation today could further propel prices to test 452.14. The maximum bullish objective for QQQ today is set at 454.10.
Conversely, if buyers fail to support 447.73 during the regular session, bears will attempt to drive prices down towards the 445.43 level. Weakness here could see a deeper decline to 444.09. Continued bearish activity would likely result in further downward pressure towards 442.53. A breakdown below this support might lead to today&#8217;s low-end bearish target of 440.78.
Apple Inc. (AAPL)
Apple is trading around our pivot area of 196.01. Bulls must defend this level to encourage upward momentum, initially targeting the 197.00 region. A successful bullish push could further lift prices to 197.69. Should buyers sustain strong momentum throughout today&#8217;s session, we anticipate a move towards our primary bullish objective of 198.79.
However, if the 196.01 level proves vulnerable, expect sellers to target an initial move down towards 195.25.&nbsp;
Continued weakness would prompt bears to seek lower prices at 194.40. An escalation in bearish activity could bring 193.95 into focus. If this support level deteriorates, sellers may aggressively push towards our daily bearish objective at 192.76.
Microsoft Corp. (MSFT)
Microsoft is presently trading around the important 373.48 level. Bulls are aiming for a strong upward advance towards 375.11 and need sustained buying to secure this as solid intraday support. Confirmed bullish strength above this level would likely drive prices upward toward 376.70. Extended buying strength today could propel Microsoft toward our upper bullish target at 380.59.
Conversely, a failure to sustain 373.48 as support would likely trigger bearish efforts to push the market lower towards 372.03. If selling becomes persistent below this point, anticipate additional downside pressure targeting 370.10. Further bearish momentum could drag prices down towards 368.79. A pronounced sell-off scenario today places our ultimate bearish target for Microsoft at 366.98.
NVIDIA Corporation (NVDA)
NVIDIA is currently trading around our notable pivot level at 105.23. Bullish traders aim for an upward move to establish 106.30 as firm intraday support. If buying continues actively, expect bulls to drive prices higher towards the next significant resistance at 107.51. Continued bullish momentum could subsequently propel prices toward 109.12, with our maximum bullish target on NVIDIA today set at 112.54.
If 105.23 does not hold as effective support, bears will initially target a downward move towards 103.96. Persistent selling below this mark could trigger a deeper bearish push towards 102.55. Weak price action today might encourage bears to test further support at 101.02. Should sellers maintain strong downside pressure, NVIDIA may extend its decline toward our lowest bearish target of 99.87.
Alphabet Inc Class A (GOOGL)
Alphabet is presently trading near our pivotal level of 154.95. Bulls must secure prices above this area to facilitate an advance towards 155.59. Continued bullish engagement would enable a sustained upward move towards our primary bullish target today of 157.41.
If sellers overwhelm 154.95 during regular trading, expect the bears to target lower prices around 153.93 initially. Further weakening below this level would likely push prices toward the 152.27 mark. Strong bearish activity could drive Alphabet to today&#8217;s ultimate downside target at 151.24.
Meta Platforms Inc (META)
Meta is currently fluctuating around our key pivot at 504.54. Bulls must strongly support this level to initiate an upward advance towards the critical area of 512.85. Persistent bullish strength would potentially see the market extend higher toward 520.27. A continuation of bullish sentiment today could ultimately lift prices towards our highest bullish objective at 526.29.
If 504.54 support is breached during today&#8217;s session, sellers will target a downward move towards the 500.83 level. Extended bearish momentum may result in prices declining further to test 498.03. A continued breakdown could see Meta retreating towards today&#8217;s lowest bearish target at 495.54.
Tesla Inc. (TSLA)
Tesla is trading around the crucial pivot level of 242.49. Bullish participants need an initial push upwards toward 243.98. Continued buying enthusiasm might then propel the price action upward towards the next resistance at 246.16. An environment of broader market strength could further extend Tesla&#8217;s rally to test higher at 248.37. If bullish momentum intensifies today, anticipate reaching our top bullish target at 250.25.
Should Tesla fail to maintain support at 242.49, bears will first aim to push the market downwards towards 239.92. Persistent selling here could lead to further downside activity at 238.50. If bearish participation remains active, sellers will target an aggressive move downward to today&#8217;s most extreme bearish objective at 235.74.
Final Word:&nbsp;
Today marks the end of this abbreviated trading week, as markets will observe the Good Friday holiday tomorrow. Key economic indicators for release include Housing Starts and Preliminary Building Permits for March, accompanied by the Philly Fed Business Outlook report for April. However, traders will particularly focus on the Initial and Continuing Jobless Claims data, which could significantly influence market sentiment, especially regarding expectations for future Fed actions. Additionally, at 11:45 AM ET, Federal Reserve&#8217;s Michael Barr, a current voting member, is scheduled to speak, potentially offering insights into monetary policy direction. 
Finally, traders should be aware of today&#8217;s 1:00 PM ET 5-Year TIPS auction hosted by the Treasury, adding another element of volatility. Crucially, today&#8217;s trading also coincides with Monthly Options Expiration (MOPEX), likely amplifying volatility levels due to market closure tomorrow. Exercise caution, adhere strictly to your risk management guidelines, and enjoy a relaxing three-day weekend!
The Morning Memo is curated by RIPS, a pro trader with years of experience in equities, options, and futures trading. RIPS is at the heart of the exclusive Market Clubhouse community, offering his insights, expertise, and real-time mentorship.
Start your day with a live daily market analysis, a carefully selected watch list, early access to the Morning Memo, and exclusive Market Clubhouse price levels, providing precise support and resistance indicators. When you become a member of Market Clubhouse, you will gain early access to the Morning Memo, just like this one, every single day—hours before it&#8217;s published. You will also have access to a live stream with zero latency and screen sharing, enabling you to witness Rips executing his trades in real-time and sharing his exclusive trading plans, strategies, and live decision-making.
For a limited time during our special promotion, you can join RIPS and get a full access pass to Market Clubhouse for 7 full days for just $7. Check it out at <a href="https://marketclubhouse.club/7Days/" title="https://marketclubhouse.club/7Days/">https://marketclubhouse.club/7Days/</a> where you can trade live with him and tap into his wealth of knowledge and experience. You can also catch Rips on his live day trading streams every Monday-Friday at 8 am EST on the Market Clubhouse YouTube channel: <a href="https://www.youtube.com/@MarketClubhouse" title="https://www.youtube.com/@MarketClubhouse">https://www.youtube.com/@MarketClubhouse</a>.

Equities

Broad U.S. Equity ETFs

Technicals

Opinion

Signals

AAPL

How To Trade SPY And Top Tech Stocks, As March Housing Starts Fall 11.4%

Shares of Hooker Furnishings Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFT#NASDAQ">HOFT</a>) were <a href="https://www.benzinga.com/premarket">trading lower in premarket </a>on Thursday after the fourth-quarter FY25 earnings.
The company reported <a href="https://www.benzinga.com/pressreleases/25/04/g44858894/hooker-furnishings-reports-improved-sales-in-fourth-quarter-additional-planned-cost-savings">fourth-quarter FY25 sales growth of 8%</a> year-on-year to $104.46 million, beating the analyst consensus estimate of $101.16 million.
The additional week in the current period drove the increase, contributing approximately $7.7 million to consolidated net sales.
Segment Revenue: Hooker Branded segment sales climbed 31%, Home Meridian improved 21.7%, and Domestic Upholstery decreased 7%.
EPS of $(0.22) <a href="https://www.benzinga.com/earnings">missed the consensus</a> estimate of $0.16.
Gross margin contracted by 60 basis points Y/Y to 23.9%. Selling and administrative expenses increased 12% Y/Y to $25.2 million. The company reported an operating loss of $2.7 million in the quarter compared to an operating income of $340,000.
Also Read: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44850301/target-under-pressure-from-discretionary-spend-slowdown-mounting-inventory-risk-goldman-sachs-downgrades-stock">Target Under Pressure From Discretionary Spend Slowdown, Mounting Inventory Risk, Goldman Sachs Downgrades Stock</a>
The company held $6.3 million in cash and equivalents as of February 2. Net cash used in operating activities for FY25 totaled $23 million.
Cost Savings: Hooker expects fiscal 2026 cost savings, net of associated transition costs, of at least between $0.8 to $1.0 million from the Savannah warehouse exit announced in March 2025.
In addition to the $10 million in annualized cost savings announced in fiscal 2025, the company expects additional annualized cost savings of between $8 to $10 million.
Total annualized savings of these two cost-saving plans which will be realized in FY27 is $18 million &#8211; $20 million.
&#8220;While macroeconomic headwinds—including a weak housing market, lower consumer confidence and tariff uncertainty—persist, we remain focused on what we can control. We&#8217;ve accelerated cost reduction initiatives which we believe will improve operating income and cash flow,&#8221; said CEO Jeremy R. Hoff.
&#8220;We are currently evaluating a range of strategies to mitigate the current economic environment, including a 50-year low in existing home sales, and the possible impact of additional reciprocal tariffs on our operations and profitability. Tariffs add tremendous complexity and uncertainty that require us to look at our cost structure more aggressively, particularly on the lower margin, direct container side of our business.&#8221;
Price Action: HOFT shares traded lower by 0.92% at $7.5 in premarket at last check Thursday.
Read Next: <a href="https://www.benzinga.com/25/04/44850223/march-retail-sales-exceed-forecasts-says-analyst">March Retail Sales Exceed Forecasts, Analyst Notes Best-Performing Sectors</a>
Photo: Shutterstock<a href="https://www.benzinga.com/go/plus500-futures" target="_blank" rel="noreferrer noopener"></a>
<a href="https://www.benzinga.com/go/plus500-futures" rel="noreferrer noopener" target="_blank"></a>

General

HOFT

What's Going On With Furniture Company Hooker Furnishings Stock Today?

Crofelemer, a novel plant-based anti-secretory prescription drug, has been granted Orphan Drug Designation by the FDA and the European Medicines Agency (EMA) for both short bowel syndrome (SBS) and microvillus inclusion disease (MVID) and is being evaluated to serve as a potential therapeutic option to manage intestinal failure in these patients
There are currently no approved drug treatments for MVID, an ultrarare pediatric disease characterized by severe diarrhea and malabsorption that requires intensive parenteral support for nutritional and fluid management
Proof-of-concept data in MVID from this study would provide support for crofelemer's potential inclusion in the EMA's <a href="https://www.ema.europa.eu/en/human-regulatory-overview/research-development/prime-priority-medicines">PRIME</a> program for novel medicines targeting unmet medical needs and the FDA's <a href="https://www.fda.gov/regulatory-information/food-and-drug-administration-safety-and-innovation-act-fdasia/fact-sheet-breakthrough-therapies">Breakthrough Therapies</a> program
SAN FRANCISCO, CA / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 17, 2025 / <a href="https://pr.report/8vx8">Jaguar Health, Inc.</a> <a href="https://pr.report/8vx9">(NASDAQ:</a><a href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) (Jaguar) family companies <a href="https://pr.report/8vxa">Napo Pharmaceuticals</a> (Napo) and <a href="https://pr.report/8vxb">Napo Therapeutics</a> today announced that preliminary results from the ongoing pediatric investigator-initiated trial (IIT) of a novel liquid formulation of crofelemer, Jaguar's novel plant-based anti-secretory prescription drug, for various congenital diarrheal disorders (CDD), including MVID and SBS with intestinal failure (SBS-IF), will be presented by Dr. Mohamad Miqdady at the April 24-26, 2025 <a href="https://pr.report/8vxc">Annual ELITE PED-GI Congress</a> in Abu Dhabi in the United Arab Emirates.
MVID and SBS-IF, rare orphan diseases requiring intensive parenteral nutrition and support, have severe morbidity and mortality implications and impact the quality of life of both patients and their caregivers. There are currently no approved drug treatments for MVID. A key value driver would be a reduction in total parenteral nutrition (TPN).
"Patients with MVID and SBS-IF suffer from devastating diarrhea and dehydration caused by these debilitating, lifelong conditions. These patients are frequently on TPN for as long as 20 hours a day, seven days a week - and TPN carries a significant risk of morbidity, including infections, metabolic complications, and liver problems," said Dr. Miqdady, the principal investigator for this study. "I look forward to presenting preliminary, proof-of-concept results from this study at the ELITE PED-GI Congress."
This ongoing proof-of-concept study is evaluating crofelemer's potential to be safely administered to patients with MVID, SBS-IF, and other CDDs in escalating doses, improve stool formation, improve the absorption of nutrients, and lower TPN needs - which have never been achieved in an MVID patient. The study also provides the opportunity to evaluate whether any potential benefit provided by crofelemer in participating patients ceases after treatment with crofelemer is discontinued.

Biotech

JAGX

Jaguar Health Announces Preliminary Results From Ongoing Pediatric Investigator-Initiated Trial Of A Novel Liquid Formulation Of Crofelemer Will Be Presented By Dr. Mohamad Miqdady At April 24-26, 2025 Annual ELITE PED-GI Congress in Abu Dhabi in the United Arab Emirates

Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>), a leader in innovative memory and storage solutions, today announced a market segment-based reorganization of its business units to capitalize on the transformative growth driven by AI, from data centers to edge devices.
Micron has maintained multiple generations of industry leadership in DRAM and NAND technology and has the strongest competitive positioning in its history. Micron's industry-leading product portfolio, combined with world-class manufacturing execution enables the development of differentiated solutions for its customers across end markets. As high-performance memory and storage become increasingly vital to drive the growth of AI, this Business Unit reorganization will allow Micron to stay at the forefront of innovation in each market segment through deeper customer engagement to address the dynamic needs of the industry.
Micron will begin transitioning to this new business structure immediately. The transition will be complete early in the company's fiscal fourth quarter, which begins on May 30, 2025. Micron will report financial results under the new business structure starting with the fourth quarter of fiscal year 2025. The four business units will be:
<ul>
<li>Cloud Memory Business Unit (CMBU): Focused on memory solutions for large hyperscale cloud customers, and high-bandwidth memory (HBM) for all data center customers. Raj Narasimhan, Senior Vice President and General Manager, who has led the Compute and Networking Business Unit (CNBU), will lead CMBU.</li>
<li>Core Data Center Business Unit (CDBU): Focused on memory solutions for OEM data center customers and storage solutions for all data center customers. Jeremy Werner, Senior Vice President and General Manager, who has led the Storage Business Unit (SBU), will lead CDBU.</li>
<li>Mobile and Client Business Unit (MCBU): Focused on memory and storage solutions for mobile and client segments. Mark Montierth, Corporate Vice President and General Manager, who has led the Mobile Business Unit (MBU), will lead MCBU.</li>
<li>Automotive and Embedded Business Unit (AEBU): Focused on memory and storage solutions for the automotive, industrial and consumer segments. Kris Baxter, Corporate Vice President and General Manager, who has led the Embedded Business Unit (EBU), will lead AEBU.</li>
</ul>
All four business units will continue to report to Sumit Sadana, Executive Vice President and Chief Business Officer.

Management

Micron Technology To Complete Business Reorganization By Early Fiscal Q4 2025; To Form 4 New Business Units; Raj Narasimhan To Lead Cloud Memory Business Unit; Jeremy Werner To Lead Core Data Center Business Unit

JP Morgan analyst Samik Chatterjee maintains Corning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLW#NYSE">GLW</a>) with a Overweight and lowers the price target from $62 to $50.

JP Morgan Maintains Overweight on Corning, Lowers Price Target to $50

Sadot Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) ("Sadot Group", "Sadot", or the "Company"), an emerging player in the global agri-food supply chain, is proud to announce that its newly established subsidiary, Sadot Korea, has successfully executed its first international commodity trades. These initial transactions involved sourcing food products from Australia and Indonesia, with final delivery to key markets in Kenya and other countries.
The launch of Sadot Korea, announced on March 26, 2025, represents a major milestone in the Company's strategy to expand its footprint in Northeast Asia. Leveraging South Korea's robust logistics and trade infrastructure, Sadot aims to establish the country as a hub for global agri-trade activity.

SDOT

Sadot Group Inc Announces First Commodity Trades Through New South Korea Subsidiary

Stifel analyst Rick Wise maintains Abbott Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABT#NYSE">ABT</a>) with a Buy and raises the price target from $135 to $145.

Stifel Maintains Buy on Abbott Laboratories, Raises Price Target to $145

TYSONS, Va. and INDIANAPOLIS, April 17, 2025 (GLOBE NEWSWIRE) -- The Indiana Fever and WTHR, the TEGNA owned NBC affiliate in Indianapolis, today announced a multi-year extension of their landmark distribution agreement to deliver more exciting basketball action to central Indiana fans than ever before.
WTHR and WALV, TEGNA's MeTV affiliate, will air 18 games locally, giving fans across central Indiana unprecedented access to watch the Fever in action as they fight for a return to the WNBA playoffs. Last season, WTHR's coverage elevated Indiana Fever viewership to new heights as the team's local broadcast home, broadening the fan base beyond hardcore sports enthusiasts. Fever games on WTHR were watched in nearly two-thirds more homes than nationally televised matchups, boasting a 63% household ratings increase over national network games.

TGNA

Indiana Fever And WTHR Announce Multi-year Extension Of Distribution Agreement To Deliver More Exciting Basketball Action To Central Indiana Fans

Acme United (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ACU#AMEX">ACU</a>) reported quarterly earnings of $0.41 per share which missed the analyst consensus estimate of $0.59 by 30.51 percent. This is a 5.13 percent increase over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $45.96 million which missed the analyst consensus estimate of $46.98 million by 2.17 percent. This is a 2.23 percent increase over sales of $44.96 million the same period last year.

Earnings

Earnings Misses

Acme United Q1 EPS $0.41 Misses $0.59 Estimate, Sales $45.96M Miss $46.98M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.tetratech.com%2F&amp;esheet=54239498&amp;newsitemid=20250416943687&amp;lan=en-US&amp;anchor=Tetra+Tech%2C+Inc.&amp;index=1&amp;md5=89c41e10623e059dc387961391a88704">Tetra Tech, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTEK#NASDAQ">TTEK</a>), a leading provider of high-end consulting and engineering services in water, environment, and sustainable infrastructure, announced today that the City of Bartlesville, Oklahoma, has awarded Tetra Tech a contract to provide engineering design and technical services for the first indirect potable reuse (IPR) project to be permitted within the State of Oklahoma.
Building upon Tetra Tech's initial IPR pilot study, Tetra Tech engineers and technical specialists will now design innovative IPR solutions to expand the Chickasaw Wastewater Treatment Plant's capacity by 15 percent. Tetra Tech will use advanced treatment processes to treat up to 50 percent of daily wastewater flows which will be redirected several miles upstream into the Caney River to be recaptured, retreated, and distributed through the City's water system during times of extreme drought.
"Tetra Tech is pleased to partner with the City of Bartlesville on this innovative project, the first indirect potable reuse facility in Oklahoma," said Dan Batrack, Tetra Tech Chairman and CEO. "We will use our Leading with Science&#xAE; approach to deliver advanced water reuse solutions that help extend Bartlesville's water supply by up to 40 years and support the State of Oklahoma's forward-looking ‘Water for 2060' goals."
&nbsp;

Contracts

TTEK

Tetra Tech Announces The City Of Bartlesville, Oklahoma Has Awarded A Contract To Provide Engineering Design And Technical Services For First Indirect Potable Reuse Project To Be Permitted Within The State Of Oklahoma

WIIM

SLNH

Soluna Holdings shares are trading higher after the company announced it signed a term sheet to power the Ellen data center project.

SOUTHLAKE, Texas and DUBAI, United Arab Emirates, April 17, 2025 /PRNewswire/ --&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4407047-1&amp;h=491652646&amp;u=https%3A%2F%2Fwww.sabrehospitality.com%2F%3Futm_source%3Dsabre%26utm_medium%3Dpr%26utm_campaign%3Dmktg_md_WebContent%26utm_content%3Dsh_website_pr&amp;a=Sabre+Hospitality">Sabre Hospitality</a>, a division of&nbsp;<a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4407047-1&amp;h=3087257568&amp;u=http%3A%2F%2Fsabre.com%2F&amp;a=Sabre+Corporation">Sabre Corporation</a>&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SABR#NASDAQ">SABR</a>) a leading global travel technology company, has announced a renewal agreement with Kerzner International, optimizing its distribution with <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4407047-1&amp;h=1679536891&amp;u=https%3A%2F%2Fwww.sabrehospitality.com%2Fresources%2Farticle%2Fpersonalized-experiences-how-retailing-software-meets-hospitalitys-growing-demand%2F&amp;a=retailing+capabilities">retailing capabilities</a> through Sabre's SynXis platform. By leveraging the SynXis Booking Engine, Kerzner will be offering ancillaries alongside room reservations. Additionally, Kerzner has renewed its agreement to distribute hotel content through Sabre Hospitality's Global Distribution System network.&nbsp;

SABR

Sabre's Division Sabre Hospitality Renews Agreement With Kerzner International To Optimize Distribution With Retailing Capabilities Through Sabre's SynXis Platform

Snap-On Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNA#NYSE">SNA</a>) reported disappointing expected <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44859295/snap-on-announces-first-quarter-2025-results" rel="noreferrer noopener">first-quarter 2025 results</a>, falling short of both revenue and earnings consensus estimates.
Here&#8217;s a breakdown of the report:
<ul>
<li>Quarterly net sales reached $1.141 billion, reflecting a 3.5% year-over-year increase and below the consensus estimate of $1.20 billion.</li>
<li>Sales were impacted by a 2.3% organic decline and a $13.9 million negative effect from unfavorable foreign currency translation.&nbsp;&nbsp;&nbsp;</li>
<li>The gross margin expanded by 23 bps to 50.7%, and gross profit fell 3.1% year over year to $578.5 million.</li>
<li>Financial services revenue rose to $102.1 million, with operating earnings at $70.3 million, up from $99.6 million and $68.3 million, respectively, in 2024.</li>
<li>Consolidated operating earnings were $313.4 million, or 25.2% of revenues, compared to $339.2 million, or 26.5% of revenues, in 2024, which included an $11.3 million legal payments benefit.</li>
<li>EPS for the quarter was $4.51, down from $4.91 YoY, below the consensus of $4.84.</li>
<li>Operating cash flow for the quarter totaled $298.5 million, compared to $348.7 million a year ago, with $1.434 billion in cash and equivalents at the quarter&#8217;s end.</li>
</ul>
Sales by segments:
<ul>
<li>Commercial &amp; Industrial $343.9 million (-2.9% YoY)</li>
<li>Snap-on Tools $462.9 million (-6.8% YoY)</li>
<li>Repair Systems &amp; Information $475.9 million (+3.7% YoY).</li>
</ul>
&#8220;As we move forward, we believe strongly in our long-established strategy to largely produce in the countries and regions where we sell and in our broad manufacturing capacity in the U.S., fortified by extensive facilities, enabled by deep process know-how, and fueled by experienced associates… all structural advantages that position us well to navigate today&#8217;s world,&#8221; said Snap-on CEO Nick Pinchuk.
&#8220;These are times of expanding turbulence. We are, however, confident, holding great belief in the criticality of our markets across essential repair, the considerable capabilities of our battle-tested team, and the power of our continuing investments in product, brand, and people.&#8221;
Outlook 2025: Snap-on expects to continue demonstrating resilience, focusing on growth in automotive repair and expanding into adjacent markets and critical industries.
The company plans to spend approximately $100 million on capital expenditures in 2025, with $22.9 million already spent in the first quarter.
Snap-on anticipates an effective income tax rate for 2025 in the range of 22% to 23%.
Price Action: Snap-on shares closed 1.50% lower at $332 on Wednesday.
Photo: Shutterstock

Guidance

Snap-On's Q1 Results Underwhelm, CEO Stresses Resilience And Strategic Advantage Moving Forward

CYCU

Cycurion shares are trading higher after the company reported a year-over-year increase in FY24 EPS results.

Lockheed Martin Appoints Evan Scott As Senior Vice President And CFO; Effective Immediately

Fidelity National Information Services Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) on Thursday unveiled two strategic moves—acquiring Global Payments&#8217; Issuer Solutions unit and <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/b44859301/fis-announces-sale-of-worldpay-stake-and-strategic-acquisition-of-global-payments-issuer-solutions" rel="noreferrer noopener">selling its remaining stake in Worldpay.</a>
What Happened: The Jacksonville, Florida-based firm agreed to purchase Global Payments&#8217; Issuer Solutions arm in a transaction valued at $13.5 billion. The deal includes $1.5 billion in projected tax-related benefits, resulting in a net outlay of $12 billion.
Simultaneously, Fidelity National will offload its 45% stake in Worldpay to Global Payments for $6.6 billion in pre-tax proceeds.
Fidelity National CEO Stephanie Ferris described the acquisition as a &#8220;high-margin&#8221; growth opportunity.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44857887/taiwan-semiconductor-q1-surges-41-in-sales-boosted-by-ai-chip-demand-expanded-margins" rel="noreferrer noopener">Taiwan Semiconductor CFO Anticipates Tariffs Impact But Has Not Seen Change In Customer Behavior Yet, Issues Strong Q2 Outlook</a>
Why It Matters: The Issuer Solutions platform processes over 40 billion transactions annually, serving clients across more than 75 countries.
It is expected to bolster Fidelity National&#8217;s existing suite of services in debit and banking infrastructure. It could also broaden access to a $28 billion global issuer market—including $15 billion in the U.S. alone.
&#8220;Issuer Solutions&#8217; globally scaled credit processing capabilities are highly complementary to FIS&#8217; established debit processing capabilities, strengthening our broader banking and capital markets offering,&#8221; Ferris said.
Separately, GTCR—which acquired a 55% majority stake in Worldpay from Fidelity National in 2023—will now sell the payments<a href="https://www.benzinga.com/pressreleases/25/04/n44859362/gtcr-announces-sale-of-worldpay-to-global-payments-for-24-25-billion-in-conjunction-with-transform" target="_blank" rel="noreferrer noopener"> firm to Global Payments for $24.25 billion.</a> The private equity firm will receive 59% cash and 41% stock consideration as part of the Worldpay transaction.
Upon closing, GTCR will own shares representing 15% of Global Payments&#8217; outstanding shares.
CEO Charles Drucker will continue to lead the Worldpay team through the transition and future integration.
What&#8217;s Next: Fidelity National intends to finance the acquisition with $8 billion in new debt alongside proceeds from the Worldpay sale.
The purchase price for Issuer Solutions reflects a valuation of approximately 9 times expected 2025 EBITDA. The Worldpay sale to Global Payments stands at about 10.5 times expected 2025 EBITDA.
These two interlinked transactions are expected to close in the first half of 2026.
Following completion, Fidelity National plans to momentarily pause share repurchases and M&amp;A activity to prioritize reducing its debt.
1Q 2025&nbsp;Update
Fidelity National will release official earnings release scheduled for May 6. The company said it reported total preliminary revenue of about $2.5 billion versus the estimate of $2.57 billion. The <a href="https://www.investor.fisglobal.com/news-releases/news-release-details/fis-reports-full-year-2024-results-and-2025-outlook-confirms#:~:text=Full%2DYear%202024%20Financial%20Results&amp;text=approximately%20%2410.1%20billion.-,GAAP%20net%20earnings%20attributable%20to%20common%20stockholders%20from%20continuing%20operations,by%204%25%20recurring%20revenue%20growth." target="_blank" rel="noreferrer noopener">prior view</a> was $2.485 billion- $2.51 billion. This reflected adjusted and recurring revenue growth of around 4%.
Adjusted EBITDA came in at roughly $958 million, while adjusted earnings per share stood at approximately $1.21 versus the analyst consensus estimate of $1.28 (prior view: $1.17&nbsp;&#8211;&nbsp;$1.22).
Price Action: FIS shares are trading lower by 0.93% to $68.00 premarket at last check Thursday. GPN shares are trading lower by 2.29% to $82.19.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44849610/bitcoin-miners-buckle-under-april-price-pressure-but-jp-morgan-analyst-says-mara-cleanspark-held-strong" target="_blank" rel="noreferrer noopener">Bitcoin Miners Buckle Under April Price Pressure, But JP Morgan Analyst Says MARA, CleanSpark Held Strong</a></li>
</ul>
Image: Shutterstock

Fidelity National Unloads Worldpay Stake To Global Payments For $6.6 Billion, Scoops Up Issuer Unit For $12 Billion

Social Media

FUBO

Fubo Retains Exclusive Rights To Premier League In Canada Beginning With 2025-2026 Season

CMND

Clearmind Medicine shares are trading higher after the company announced the US Patent Office has issued a notice of allowance relating to its MEAI treatment for binge behavior.

Health Care

Press Releases

Helius Medical Technologies, Inc. Announces Reimbursement Payment Determination Updates from CMS for its Portable Neuromodulation Stimulator (PoNS®) Controller and Mouthpiece

Helius Medical Technologies, Inc. to Present at the 2024 ThinkEquity Conference

Helius Medical Technologies, Inc. Announces Exploration of Strategic Alternatives

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for its Portable Neuromodulation Stimulator (PoNS®) Device

Helius Announces First Portable Neuromodulation Stimulator (PoNS®) System Sale to the Veterans Affairs (VA) Healthcare System

Helius Medical Technologies, Inc. Announces Strong Enrollment of its Stroke Pivotal Study Exceeding Initial Target

Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced At-the-Market

Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study

Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device

Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface ("BCI") Technology Private Subsidiary

Comments

Helius Medical Tech

Interés en corto

Helius Medical Tech (NASDAQ:HSDT) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL